Related Experiment Video
Updated: Dec 4, 2025
Author Spotlight: Advancements in Molecular Biomarker Testing for Non-Squamous Non-Small Cell Lung Cancer
Published on: September 8, 2023
SCLC-CellMiner: A Resource for Small Cell Lung Cancer Cell Line Genomics and Pharmacology Based on Genomic Signatures
Camille Tlemsani1, Lorinc Pongor1, Fathi Elloumi1
1Developmental Therapeutics Branch, Center for Cancer Research, National Cancer Institute, NIH, Bethesda, MD 20892, USA.
Abstract:
CellMiner-SCLC (https://discover.nci.nih.gov/SclcCellMinerCDB/) integrates drug sensitivity and genomic data, including high-resolution methylome and transcriptome from 118 patient-derived small cell lung cancer (SCLC) cell lines, providing a resource for research into this "recalcitrant cancer." We demonstrate the reproducibility and stability of data from multiple sources and validate the SCLC consensus nomenclature on the basis of expression of master transcription factors NEUROD1, ASCL1, POU2F3, and YAP1. Our analyses reveal transcription networks linking SCLC subtypes with MYC and its paralogs and the NOTCH and HIPPO pathways. SCLC subsets express specific surface markers, providing potential opportunities for antibody-based targeted therapies. YAP1-driven SCLCs are notable for differential expression of the NOTCH pathway, epithelial-mesenchymal transition (EMT), and antigen-presenting machinery (APM) genes and sensitivity to mTOR and AKT inhibitors. These analyses provide insights into SCLC biology and a framework for future investigations into subtype-specific SCLC vulnerabilities.
Insights
This study introduces CellMiner-SCLC, a valuable resource for small cell lung cancer (SCLC) research. It reveals subtype-specific vulnerabilities and potential targeted therapies for this challenging cancer.
Area of Science:
- Oncology
- Genomics
- Bioinformatics
Background:
- Small cell lung cancer (SCLC) remains a recalcitrant malignancy with limited therapeutic options.
- Existing resources often lack integrated drug sensitivity and comprehensive genomic data for SCLC.
- Understanding SCLC heterogeneity is crucial for developing effective treatments.
Purpose of the Study:
- To present CellMiner-SCLC, an integrated database of drug sensitivity and multi-omic data for 118 patient-derived SCLC cell lines.
- To validate SCLC consensus nomenclature based on master transcription factor expression.
- To identify molecular networks and vulnerabilities specific to SCLC subtypes.
Main Methods:
- Integration of drug sensitivity, methylome, and transcriptome data from 118 SCLC cell lines.
- Validation of SCLC consensus nomenclature using NEUROD1, ASCL1, POU2F3, and YAP1 expression.
- Bioinformatic analysis to identify transcription networks, surface markers, and pathway associations.
Main Results:
- Demonstrated reproducibility and stability of integrated genomic and drug sensitivity data.
- Validated SCLC subtypes based on transcription factor expression, revealing links to MYC, NOTCH, and HIPPO pathways.
- Identified SCLC subsets with distinct surface markers and specific vulnerabilities, including YAP1-driven SCLCs sensitive to mTOR and AKT inhibitors.
Conclusions:
- CellMiner-SCLC provides a robust resource for advancing SCLC research.
- SCLC subtypes exhibit distinct molecular characteristics and potential therapeutic targets.
- Findings offer a framework for developing subtype-specific therapeutic strategies against SCLC.
